Funding for medical device businesses in South Africa

Three models, three completely different raises

An importer-distributor is a working-capital business: stock funding and receivables finance against private hospital groups and provincial tenders, where payment terms — not demand — are the binding constraint, and provincial payment behaviour is priced ruthlessly by funders who have seen the age analyses. A local manufacturer raises capex plus growth equity, with localisation policy and export potential strengthening the case and quality-management certification (ISO 13485) as table stakes. A device developer is a venture raise against regulatory and clinical milestones — SAHPRA licensing domestically, CE or FDA for export markets — with a credible route to market that usually runs through the distributors it will one day compete with or sell to. Pitching one model with another’s economics is the sector’s most common self-inflicted rejection.

SAHPRA is diligence item one

Licence status, the classification pathway for new devices, and quality-management certification determine whether a device business is fundable at all — investors price regulatory risk before commercial risk, and an unresolved SAHPRA position is a funding blocker, not a post-close task. For developers, the milestone structure of the raise should map to the regulatory pathway explicitly: capital tranched against classification outcomes is both easier to raise and cheaper than a lump sum priced for the full risk.

The customer-base question

Funders weigh the mix between private hospital groups (predictable payers, concentrated negotiating power) and public tenders (deep demand, punishing payment terms) — and margin durability against currency movement, since imported components price in dollars and euros while revenue lands in rand. Businesses that hedge structurally — local assembly, rand-denominated service revenue, export sales — raise on better terms than pure importers exposed on both sides.

Who funds the sector — and Caban’s position in it

Healthcare is one of Caban’s deepest sectors — the group’s recent transactions include a R160 million healthcare raise — and device businesses draw the same capital map: specialist healthcare PE and VC, corporate arms of hospital and pharma groups, DFIs with health mandates, and international healthcare investors reached through the healthcare practice. Working-capital and bridging structures fit distributors; growth equity and mezzanine fit manufacturers; milestone-tranched venture capital fits developers.

What kills medical device raises

Unresolved SAHPRA status; tender concentration presented as a pipeline; currency exposure unhedged and unacknowledged; clinical claims ahead of evidence; and distributors pitching like developers — asking venture money to fund what is structurally a receivables problem. The readiness check maps which model — and which instrument — a business actually is.

How a device-sector raise actually runs

A distributor facility closes in four to eight weeks once the debtor age analysis and stock records are clean — the preparation, not the funder, sets the clock. A manufacturer’s growth raise runs three to six months: capex quotes, offtake or order evidence, certification files and the model behind the volume step all get verified. A developer’s milestone raise takes as long as the story is honest — tranches mapped to SAHPRA classification stages close faster than lump sums because each tranche prices a smaller, named risk. In all three, the single biggest accelerant is arriving with the regulatory file complete and indexed; the single biggest delay is a licence question surfacing after term sheet.

The questions device funders will ask

• What is SAHPRA licence status — exactly, with documentation — for every device sold?
• What does the debtor age analysis show for provincial versus private customers?
• What share of revenue is consumables and service versus one-off equipment sales?
• How is currency exposure managed between imported cost and rand revenue?
• What is tender concentration, and what happened at the last renewal?
• For developers: which classification pathway, which clinical evidence, and what does each milestone cost and unlock?
• Who services the installed base, and what does that contract book look like?

The regulatory file, the age analysis and the revenue-mix split answer most of these before a meeting is needed — assembling them is the raise preparation.

The consumables annuity — the multiple inside the model

Equipment sales earn once; consumables, reagents, service contracts and spares earn monthly against an installed base — and funders price the difference heavily, because annuity revenue survives tender cycles and currency swings that equipment margins don’t. Distributors and manufacturers who deliberately build the installed-base economics — placement models that seed equipment to capture consumable streams, service contracts attached at sale — raise on materially better terms than transactional sellers with identical revenue. The strategic question before any raise: what share of next year’s revenue is already contracted or consumption-driven, and how fast can that share grow? Moving it from 20% to 40% changes the funder conversation more than doubling the pipeline does.

And keep the regulatory file live, not archival: SAHPRA positions, certificates and renewals maintained in one indexed, current folder — because the fastest device raises are the ones where the regulatory question is answered before it is asked.